Patent classifications
A61L2300/44
Minimally invasive treatment of vertebra (MITV) using a calcium phosphate combination bone cement
Featured are a biocompatible, injectable, self-setting, cohesive, bone-bonding and remodeling calcium phosphate composite material and its use in methods of repairing defective bone, e.g., in vertebroplasty augmentation and kyphoplasty.
COMPOSITION OF AT LEAST A RADIOPAQUE AGENT, METHOD FOR ITS PRODUCTION AND FILLING MATERIAL COMPRISING SUCH COMPOSITION
Composition or system of a radiopaque agent including at least a first radiopaque agent in the form of a powder and at least a second radiopaque agent in the form of granules, wherein the first radiopaque agent is an equal or different material than the second radiopaque agent; method for obtaining the composition or system, filler material and kit including such radiopaque agent composition or system.
READY-TO-USE MONOMER-FREE ACRYLIC BONE CEMENT WITH ACCELERATED IN-SITE CURING PROPERTIES
The present invention relates to a medical grade bone cement having at least two mixable components, the bone cement comprising: a first component comprising at least 20% by weight of a first polymer material in which at least 40% of the functional groups are methacrylates; and a second component comprising at least one initiator selected to cause cross-linking of said first polymer material, wherein a balance of said second component comprises at least 40% by weight of a second polymer material that does not react with said initiator; said second component being a paste.
Radioluminescent Phototherapy Eye Device
Embodiments of the present disclosure are directed to a phototherapy eye device. In an example, the phototherapy eye device includes a number of radioluminescent light sources and an anchor. Each radioluminescent light source includes an interior chamber coated with phosphor material, such as zinc sulfide, and containing a radioisotope material, such as gaseous tritium. The volume, shape, phosphor material, and radioisotope material are selected for emission of light at a particular wavelength and delivering a particular irradiance on the retina (when implanted in an eyeball). The wavelength is in the range of 400 to 600 nm and the irradiance is substantially 10.sup.9 to 10.sup.11 photons per second per cm.sup.2.
In situ solidifying complex coacervates and methods of making and using thereof
Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.
FLEXIBLE AND/OR ELASTIC BRACHYTHERAPY SEED OR STRAND
A flexible or elastic brachytherapy strand that includes an imaging marker and/or a therapeutic, diagnostic or prophylactic agent such as a drug in a biocompatible carrier that can be delivered to a subject upon implantation into the subject through the bore of a brachytherapy implantation needle has been developed. Strands can be formed as chains or continuous arrays of seeds up to 50 centimeters or more, with or without spacer material, flaccid, rigid, or flexible.
SCAFFOLDS FOR CELL COLLECTION OR ELIMINATION
A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host.
PLASTIC MATERIAL FOR DEVICES TO BE IMPLANTED INTO THE HUMAN BODY OR FOR ARTICULAR SPACERS
Biocompatible and implantable in the human body plastic material, for the obtainment of a device that can be implanted in the human body or a spacer device in order to treat a bone or a joint location, including an acrylic resin or polyethylene (PE) or low density polyethylene or high density polyethylene or ultra-high molecular weight polyethylene (UHMWPE) or polypropylene or polyamide or polyetheretherketone (PEEK) or a thermosetting resin or a mixture of the same, wherein the material can be molded and includes at least one pharmaceutical or medical substance; device implantable in the human body or spacer device for treating a bone or a joint location, obtained by the material above and method for manufacturing the material according to the present invention.
PRODUCTION OF ARTIFICIAL TISSUES COMPRISING MAGNETIC PARTICLES
The invention is comprised in the field of biomedicine, and more specifically, the field of tissue engineering. The invention specifically relates to the use of multiple magnetic domain particles that have a mean diameter greater than 25 nm, to compositions and biomaterials comprising same, and to an in vitro method for producing an artificial tissue with the magnetic particles, to the artificial tissue that can be produced by said method, and to the use of said artificial tissue for partially or completely increasing, restoring or replacing the functional activity of a damaged organ or tissue.
LIQUID RADIOEMBOLIC AGENTS AND RELATED EMBOLIZATION SYSTEMS AND METHODS OF EMBOLIZATION
A kit is provided for delivering local radiation to a tumor while also causing tumor devascularization. The kit includes a first liquid radioembolic agent for treatment of at least a first region of the tumor and a second liquid radioembolic agent for treatment of at least a second region of the tumor. The first liquid radioembolic agent includes: a biocompatible polymer or prepolymer and a first radioisotope having a first type of ionizing radiation for treatment of the first region of the tumor. The second liquid radioembolic agent includes: a biocompatible polymer or prepolymer and a second radioisotope having a second type of ionizing radiation for treatment of the second region of the tumor. The second type of ionizing radiation is different than the first type of ionizing radiation. Each of the first type of ionizing radiation and the second type of ionizing radiation is selected from the group consisting of: alpha type ionizing radiation, beta type ionizing radiation: gamma type ionizing radiation; and combinations thereof.